NCT06825169View on ClinicalTrials.gov

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2028

Conditions
Interstitial Lung Disease (ILD)
Interventions
BIOLOGICAL

NCR101 injection

Subjects will receive one NCR101 injection in Single Ascending Dose（SAD）and receive 4 NCR101 injections in Multiple Ascending Dose(SAD).

Sponsors
All Listed Sponsors
lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY

NCT06825169 - A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease | Biotech Hunter | Biotech Hunter